Mount Sinai joins effort to develop COVID-19 hyperimmune globulin product candidate
The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune globulin product, it was announced yesterday. The COVID-HIG is prepared using convalescent plasma from COVID-19 patients to potentially prevent and treat the disease in the absence of a vaccine. The collaboration, which leverages $34.6 million in funding from the Department of Defense, includes a post-exposure prophylaxis study on health care providers at high risk of COVID-19 infection and other high-risk populations.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…